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BACKGROUND: Inflammation levels are lower in East Asians than in Western people. We studied the association between high-
sensitivity hs-CRP (C-reactive protein) and adverse outcomes in Korean patients with chronic kidney disease.
METHODS AND RESULTS: We included 2018 participants from the KNOW-CKD (Korean Cohort Study for Outcome in Patients 
With Chronic Kidney Disease) between April 2011 and February 2016. The primary outcome was a composite of extended 
major cardiovascular events (eMACE) or all-cause mortality. The secondary end points were separate outcomes of eMACE, 
all-cause death, and adverse kidney outcome. We also evaluated predictive ability of hs-CRP for the primary outcome. The 
median hs-CRP level was 0.60 mg/L. During the mean follow-up of 3.9 years, there were 125 (6.2%) eMACEs and 80 (4.0%) 
deaths. In multivariable Cox analysis after adjustment of confounders, there was a graded association of hs-CRP with the 
primary outcome. The hazard ratios for hs-CRPs of 1.0 to 2.99 and ≥3.0 mg/L were 1.33 (95% CI, 0.87–2.03) and 2.08 (95% 
CI, 1.30–3.33) compared with the hs-CRP of <1.0 mg/L. In secondary outcomes, this association was consistent for eMACE 
and all-cause death; however, hs-CRP was not associated with adverse kidney outcomes. Finally, prediction models failed to 
show improvement of predictive performance of hs-CRP compared with conventional factors.
CONCLUSIONS: In Korean patients with chronic kidney disease, the hs-CRP level was low and significantly associated with 
higher risks of eMACEs and mortality. However, hs-CRP did not associate with adverse kidney outcome, and the predictive 
performance of hs-CRP was not strong.
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Cardiovascular disease (CVD) is the leading cause of death in patients with chronic kidney disease (CKD), and CVD and CKD share common risk factors of smoking, obesity, hypertension, diabetes mellitus, and dyslipidemia. There is an intimate connec-tion between the kidney and the heart. For example, a 
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deteriorating heart can lead to decreased kidney func-
tion through multiple mechanisms1–3 and vice versa.4,5 
Notably, a recent cohort study showed that lower kid-
ney function based on cystatin-C was an independent 
predictor of heart failure among patients with CKD.6 
In addition, major adverse cardiac and cerebrovascu-
lar events occur more frequently in patients with CKD 
than in those without kidney disease,7 and people at 
high risk of cardiovascular events (CVEs) also have in-
creased risk of CKD.8
It is well known that inflammation plays a key role 
in promoting vascular injury and atherosclerosis in 
patients with CVD.9–11 In fact, persistently elevated 
inflammation well predicts future development or 
recurrence of CVEs and deaths.12–14 In addition, 
serum concentrations of inflammatory markers are 
elevated in patients with CKD compared with those 
with normal kidney function, and higher levels of 
these markers have been reported to be associated 
with worsening kidney function.15–17 Interestingly, 
previous studies have shown that levels of serum 
hs-CRP (high-sensitivity C-reactive protein), a 
well-known marker of inflammation, is lower in the 
East Asian population than in the Western popu-
lation.14,18–22 Because CKD is generally considered 
a highly inflamed status, it can be presumed that 
hs-CRP level is substantially increased even in East 
Asian patients with CKD. Nevertheless, we previ-
ously reported that the median hs-CRP level was 
only 0.6  mg/L among participants of the KNOW-
CKD (Korean Cohort Study for Outcome in Patients 
With Chronic Kidney Disease).23 This finding led us 
to question whether such low-grade inflammation 
can still serve as a biomarker in our cohort partic-
ipants. Thus, we studied the associations of hs-
CRP level with various adverse clinical outcomes in 
Korean patients with CKD.
METHODS
Because of ethical issues and data protection regu-
lations, data that support the findings of the present 
study cannot be made publicly available.
Ethics Approval and Consent to 
Participate
All procedures performed in the participants were in ac-
cordance with the ethical standards of the institutional 
and national research committees at which the studies 
were conducted (institutional review board approval 
number H-1104-089-359) and with the 1964 Helsinki 
declaration and its later amendments or comparable 
ethical standards. The study protocol was approved 
by the institutional review board at each participating 
clinical center. Written informed consent was obtained 
from all study participants.
Study Population
KNOW-CKD is an ongoing, nationwide, multicenter, 
prospective cohort study initiated in 2011. The detailed 
design and methods of the KNOW-CKD study have 
been previously published (NCT01630486 at http://
www.clini caltr ials.gov).24 Between 2011 and 2016, 
2238 patients with CKD stages 1 to 5 who were aged 
20 to 75 years before dialysis therapy were recruited 
for this study. For our current study, we excluded 190 
patients who did not have measured hs-CRP level at 
baseline. An additional 30 patients who undertook 
baseline examination only but dropped out were also 
excluded because information on outcome events 
was not available. Thus, a total of 2018 patients was 
included in the final analysis (Figure S1).
CLINICAL PERSPECTIVE
What Is New?
• Median serum concentration of hs-CRP (high-sen-
sitivity C-reactive protein) was only 0.6 mg/L, and 
the incidence rate of cardiovascular events was low 
in Korean patients with chronic kidney disease.
• In these patients with low-grade inflammation, 
higher hs-CRP levels were associated with in-
creased risk of extended major cardiovascu-
lar events and all-cause death compared with 
those without inflammation.
• However, hs-CRP did not associate with ad-
verse kidney outcome, and the predictive per-
formance of hs-CRP was not strong.
What Are the Clinical Implications?
• Low-grade inflammation level may partly explain 
the low incidence of cardiovascular events in 
Korean patients with chronic kidney disease.
• Our findings highlight the importance of hs-CRP 
as a biomarker but also show its limited value in 
risk stratification for adverse outcomes in this 
population.
Nonstandard Abbreviations and Acronyms
CVE cardiovascular event
eMACE  extended major cardiovascular 
event
KNOW-CKD  Korean Cohort Study for Outcome 
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Exposure and Outcome Ascertainment
The main predictor of this study was level of hs-CRP. 
To examine the associations of hs-CRP with adverse 
outcomes, patients were classified into the following 
3 groups according to risk of hs-CRP proposed by 
the Centers for Disease Control and Prevention and 
the American Heart Association: <1.0, 1.0 to 2.99, and 
≥3.0 mg/L.25 In addition, we further analyzed this as-
sociation with hs-CRP as a continuous variable in 1-SD 
increments.
The primary outcome of interest was a composite 
of eMACE or all-cause death. eMACE was defined as 
the first occurrence of cardiac death and nonfatal CVEs 
including any nonfatal coronary artery event (unstable 
angina, myocardial infarction, or coronary interven-
tion/surgery), hospitalization for heart failure, ischemic 
or hemorrhagic stroke, or symptomatic arrhythmia. 
The secondary end points were individual outcomes 
of eMACE, all-cause mortality, and CKD progression. 
CKD progression was defined as a composite CKD 
outcome ≥50% decline in estimated glomerular filtra-
tion rate (eGFR) during follow-up or onset of end-stage 
kidney disease including initiation of dialysis or kidney 
transplantation. All patients had been under close ob-
servation for occurrence of events, and patients who 
reached the end points were reported by each center. 
Regardless of visit schedule, all events and the date of 
occurrence were thoroughly recorded and reported by 
each participating center. The study observation closed 
on March 31, 2018.
Statistical Analysis
Detailed data collection, and statistical analysis meth-
ods were described in Data S1. The Cox proportional 
hazards model was applied to determine the asso-
ciations between hs-CRP and study outcomes after 
adjustment for confounding variables. Variables that 
showed statistical significance in univariable Cox 
analyses and factors known to have clinical impact 
on CVEs were selected for the adjustment models. 
Model 1 represents a hazard ratio (HR) without ad-
justment. Model 2 was adjusted for age; sex; alcohol 
intake; smoking status; Charlson comorbidity index; 
socioeconomic status; educational status; body 
mass index (BMI); systolic blood pressure; and use 
of medications, including renin-angiotensin system 
blockers, β-blockers, diuretics, and statins. Model 
3 further included laboratory parameters of eGFR, 
urine protein-to-creatinine ratio, high-density lipopro-
tein cholesterol, serum phosphate, and albumin. The 
results are expressed as HR and 95% CI. To account 
for time-dependent changes of hs-CRP, we also 
constructed a time-updated model. In the KNOW-
CKD, hs-CRP level was measured at baseline, year 
1, and year 3. Thus, in this model, hs-CRP and other 
time-dependent variables of BMI, systolic blood 
pressure, high-density lipoprotein cholesterol, serum 
phosphate, and albumin were treated as time-varying 
exposures. Proportional hazards assumptions were 
confirmed using Schoenfeld residuals. For second-
ary analyses for CKD outcome and eMACE, we used 
a cause-specific hazard function for a competing risk 
model. In this analysis, deaths that occurred before 
CKD events and noncardiac deaths that occurred 
before eMACE were treated as competing risks and 
censored. In other words, subjects experiencing a 
competing risk event are removed from the risk set 
in a cause-specific hazard model.26,27 Kaplan–Meier 
curve analysis for the composite outcome and all-
cause death was employed to derive survival rates, 
and differences between groups were compared 
by a log-rank test. Cumulative incidence curves for 
individual renal and cardiovascular outcomes were 
derived using cumulative incidence functions con-
sidering competing risks. The Gray test was used 
for these 2 outcomes to test statistically significant 
differences among groups. To prove the findings of 
primary analysis, sensitivity analysis was performed 
in tertile and quintile groups of hs-CRP level.
Furthermore, we examined effect modification of hs-
CRP for the primary outcome in prespecified subgroups 
by age (<60 and ≥60 years); sex; BMI (<25 and ≥25 kg/
m2); presence of diabetes mellitus; and previous CVD, 
baseline GFR (<50 and ≥50 mL/min per 1.73 m2), serum 
albumin (<4.0 and ≥4.0 g/dL), and low-density lipoprotein 
cholesterol levels (<100 and ≥100 mg/dL). To compare 
predictive ability of hs-CRP, we calculated Harrell c-sta-
tistics, area under the receiver-operating characteristics 
curves, category-free net reclassification improvement, 
and integrated discrimination improvement for models. 
The base model included conventional factors of age, 
sex, alcohol intake, smoking status, Charlson comorbidity 
index, socioeconomic status, educational status, base-
line BMI, systolic blood pressure, high-density lipoprotein 
cholesterol, total cholesterol, and albumin. The base+hs-
CRP model additionally adjusted for hs-CRP in addition 
to the base model. The renal model additionally adjusted 
for baseline eGFR and baseline urine protein-to-creati-
nine ratio in addition to the base model. Finally, the re-
nal+hs-CRP model was constructed after hs-CRP was 
added to the renal model. Data were analyzed using 
STATA version 14.2 software (StataCorp, College Station, 
TX). P<0.05 were considered statistically significant.
RESULTS
Baseline Characteristics
Demographic, clinical, and laboratory details of the 
patients according to hs-CRP group are presented 
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Table 1. Baseline Characteristics of Patients According to hs-CRP Groups
hs-CRP Group
Total, N=2018 P Value
P Value 
for Trend<1.0 mg/L, N=1233
1.0 to 2.99 mg/L, 
N=508 ≥3.0 mg/L, N=277
Demographic data
Age, y 54.0 (44.0–63.0) 55.0 (47.0–64.0) 57.0 (46.0–65.0) 55.0 (45.0–63.0) 0.02 <0.01
Sex, male 726 (58.9) 322 (63.4) 175 (63.2) 1223 (60.6) 0.14 0.07
BMI, kg/m2 24.0±3.1 25.4±3.4 25.6±3.7 24.6±3.4 <0.01 <0.01
SBP, mm Hg 126.7±16.0 129.2±16.6 130.0±16.1 127.8±16.2 <0.01 <0.01
Economic status 0.05 0.06
≥$4905/mo 306 (24.8) 132 (26.0) 64 (23.1) 502 (24.9)
$1635 to 4905/mo 674 (54.7) 250 (49.2) 137 (49.5) 1061 (52.6)
<$1635/mo 253 (20.5) 126 (24.8) 76 (27.4) 455 (22.5)
Education 0.03 0.01
<9 y 275 (22.3) 133 (26.2) 86 (31.0) 494 (24.5)
9 to 12 y 443 (35.9) 172 (33.9) 90 (32.5) 705 (34.9)
≥12 y 515 (41.8) 203 (40.0) 101 (36.5) 819 (40.6)
Smoking status 0.01 0.09
Never 687 (55.7) 263 (51.8) 136 (49.1) 1086 (53.8)
Current 171 (13.9) 101 (19.9) 49 (17.7) 321 (15.9)
Former 375 (30.4) 144 (28.3) 92 (33.2) 611 (30.3)
Alcohol intake 0.65 0.42
Mild, none or <1 g/d 986 (80.0) 391 (77.0) 219 (79.1) 1596 (79.1)
Moderate, 1 g to 19 g/d 116 (9.4) 52 (10.2) 29 (10.5) 197 (9.8)
High, ≥20 g/d 131 (10.6) 65 (12.8) 29 (10.5) 225 (11.1)
Comorbidities
Hypertension 1171 (95.0) 495 (97.4) 270 (97.5) 1936 (95.9) 0.02 0.01
Diabetes mellitus 380 (30.8) 189 (37.2) 109 (39.4) 678 (33.6) <0.01 <0.01
COPD 3 (0.2) 3 (0.6) 6 (2.2) 12 (0.6) <0.01 <0.01
Connective tissue disease 62 (5.0) 36 (7.1) 25 (9.0) 123 (6.1) 0.02 0.01
Liver disease 23 (1.9) 14 (2.8) 9 (3.2) 46 (2.3) 0.27 0.11
Peripheral vascular disease 40 (3.2) 21 (4.1) 14 (5.1) 75 (3.7) 0.30 0.12
Cardiovascular disease 64 (5.2) 33 (6.5) 25 (9.0) 122 (6.0) 0.05 0.02
Congestive heart failure 15 (1.2) 3 (0.6) 13 (4.7) 31 (1.5) <0.01 <0.01
Charlson comorbidity index 2.2±1.6 2.4±1.6 2.6±1.7 2.3±1.6 <0.01 <0.01
Primary kidney disease <0.01 0.04
Diabetic nephropathy 292 (23.7) 144 (28.3) 67 (24.2) 503 (24.9)
Hypertensive 218 (17.7) 102 (20.1) 73 (26.4) 393 (19.5)
Glomerulonephritis 411 (33.3) 151 (29.7) 73 (26.4) 635 (31.5)
PKD 228 (18.5) 71 (14.0) 37 (13.4) 336 (16.7)
Others 84 (6.8) 40 (7.9) 27 (9.7) 151 (7.5)
Medication
RAS blockers 963 (78.1) 414 (81.5) 228 (82.3) 1605 (79.5) 0.08 0.20
Statin 649 (52.6) 266 (52.4) 135 (48.7) 1050 (52.0) 0.49 0.31
Laboratory parameters
eGFR, mL/min per 1.73 m2 55.7±31.9 51.7±28.9 48.2±29.5 53.6±31.0 <0.01 <0.01
BUN, mg/dL 27.7±15.8 28.1±14.9 30.0±16.4 28.1±15.7 0.08 <0.01
WBC, 103/μL 6.3±1.8 6.9±1.9 7.5±2.2 6.6±1.9 <0.01 <0.01
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age was 55.0 (IQR 45.0–63.0) years, and 1223 
(60.6%) were men. The median hs-CRP level was 
0.6 mg/L (IQR 0.2–1.7). The distribution of hs-CRP is 
presented in Figure S2. Patients with higher hs-CRP 
level were older, more likely to be men and current 
smokers, and had more comorbid conditions such 
as diabetes mellitus and previous CVDs than those 
with lower hs-CRP level. In addition, these patients 
had higher blood pressure readings and BMI and 
lower eGFR.
Association of hs-CRP With the Primary 
Outcome
We analyzed whether hs-CRP level was associated with 
adverse clinical outcomes. During a mean follow-up of 
3.9±1.7 years, the primary composite outcome occurred 
in 184 (9.1%) patients, with an incidence rate of 2.32 per 
100 person-years. There were 94 (7.6%), 49 (9.7%), and 
41 (14.8%) primary outcome events in patients with hs-
CRP levels <1.0, 1.0 to 2.99, and ≥3.0 mg/L, respectively. 
The corresponding incidence rates were 1.93, 2.41, and 
4.01 per 100 person-years, respectively (Table  S1). In 
addition, time to primary outcome events was signifi-
cantly shorter among patients with higher hs-CRP levels 
(Figure 1A). Multivariable Cox models after sequential ad-
justments confirmed this association (Table 2). In the fully 
adjusted model, compared with hs-CRP of <1.0 mg/L, 
the HRs for hs-CRP of 1.0 to 2.99 and ≥3.0 mg/L were 
1.33 (95% CI, 0.87–2.03) and 2.08 (95% CI, 1.30–3.33), 
respectively (Table 2; model 3). In additional analysis with 
hs-CRP as a continuous variable, a 1-SD increase in 
hs-CRP was associated with a 5.4% higher risk of the 
primary outcome.
A time-updated hs-CRP model also yielded sim-
ilar findings (Table 2; model 4). The results showed 
that patients with hs-CRP ≥3.0 mg/L had a 2.7-fold 
higher risk of the composite outcome (95% CI, 1.55–
4.77) than those with hs-CRP <1.0 mg/L. With con-
tinuous modeling, there was a 3.9% higher risk of an 
adverse outcome per 1-SD increase in hs-CRP level.
Secondary Outcome Analysis
We further analyzed the associations of hs-CRP with 
the prespecified secondary outcomes. eMACE oc-
curred in 125 (6.2%) patients, and the incidence rate 
for this outcome was significantly higher in patients 
with higher hs-CRP level (Table  S1). In agreement 
with the results of primary outcome analysis, the mul-
tivariable Cox model consistently showed a higher 
risk of eMACE among patients with higher hs-CRP 
levels. In the fully adjusted model, the HR for hs-CRP 
≥3.0 mg/L was 1.86 (95% CI, 1.04–3.42) compared 
with hs-CRP <1.0 mg/L (Table 2 and Figure 1B). In 
the analysis for all-cause mortality, 80 (4.0%) deaths 
from any cause occurred during follow-up. Patients 
with hs-CRP ≥3.0  mg/L had a 2.57-fold (95% CI, 
1.26–5.22) higher risk of death than those with hs-
CRP <1.0 mg/L. There was no significant difference 
in risk of eMACE or all-cause death between patients 
with hs-CRP <1.0 mg/L and those with hs-CRP of 1.0 
to 2.99 mg/L (Table 2 and Figure 1C). Finally, a total 
of 544 (27.0%) patients developed the composite 
hs-CRP Group
Total, N=2018 P Value
P Value 
for Trend<1.0 mg/L, N=1233
1.0 to 2.99 mg/L, 
N=508 ≥3.0 mg/L, N=277
Hemoglobin, g/dL 12.8±2.0 13.0±2.0 12.6±2.1 12.8±2.0 0.02 0.19
Hematocrit, % 38.0±5.6 38.5±5.7 37.3±5.7 38.0±5.6 0.02 0.32
Albumin, g/dL 4.2±0.4 4.2±0.4 4.1±0.4 4.2±0.4 0.01 <0.01
hs-CRP, mg/L 0.3 (0.1–0.5) 1.6 (1.2–2.1) 5.8 (3.9–11.0) 0.6 (0.2–1.7) <0.01 <0.01
Ferritin, ng/mL 90.9 (48.3–168.0) 110.9 (59.0–180.0) 121.0 (64.4–208.0) 98.1 (53.0–175.7) <0.01 <0.01
Phosphate, mg/dL 3.7±0.7 3.7±0.7 3.7±0.6 3.7±0.7 0.88 0.72
Fasting glucose, mg/dL 108.3±36.8 112.6±38.1 117.1±51.9 110.6±39.6 <0.01 <0.01
Tchol, mg/dL 173.4±38.8 177.0±40.4 172.6±37.0 174.2±39.0 0.17 0.38
HDL-C, mg/dL 51.5±16.1 46.6±13.9 45.4±13.1 49.5±15.4 <0.01 <0.01
TG, mg/dL 125.0 (88.0–177.0) 150.5 (102.5–222.5) 137.0 (87.0–190.0) 132.0 (92.0–192.0) <0.01 <0.01
LDL-C, mg/dL 96.1±32.3 99.5±32.6 97.9±28.4 97.2±31.9 0.11 0.02
uPCR, g/g 0.5 (0.1–1.4) 0.5 (0.2–1.5) 0.6 (0.2–1.8) 0.5 (0.1–1.5) 0.04 0.01
uACR, mg/g 342.0 (70.5–1030.5) 342.3 (79.3–1074.9) 385.5 (105.9–1273.5) 347.9 (77.5–1049.3) 0.18 0.07
Data are presented as mean±SD, number (%), or as median and interquartile ranges. BMI indicates body mass index; BUN, blood urea nitrogen; COPD, 
chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high-sensitivity 
C-reactive protein; SBP, systolic blood pressure; HbA1c, glycated hemoglobin; LDL-C, low-density lipoprotein cholesterol; PKD, polycystic kidney disease; 
RAS, renin-angiotensin system; Tchol, total cholesterol; TG, triglyceride; uACR, urine albumin-to-creatinine ratio; uPCR, urine protein-to-creatinine ratio; and 
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kidney outcome in our cohort. However, hs-CRP 
level was not associated with adverse kidney out-
comes, and the HRs for hs-CRP of 1.0 to 2.99 and 
≥3.0 mg/L were 1.03 (95% CI, 0.64–1.67) and 0.68 
(95% CI, 0.32–1.45), respectively, compared with hs-
CRP <1.0 mg/L (Table 2 and Figure 1D).
Sensitivity Analysis
To validate our findings, we then performed sensitivity 
analysis in tertile groups of hs-CRP levels. In line with 
the primary analysis, there was a graded association 
between hs-CRP and the primary outcome. The HRs 
for the middle and highest tertiles of hs-CRP were 1.23 
(95% CI, 0.76–2.00) and 1.92 (95% CI, 1.20–3.06), re-
spectively, compared with the lowest tertile. This asso-
ciation was consistent in additional models by quintile 
of hs-CRP (Table S2).
Subgroup Analysis
We examined effect modification of hs-CRP in pre-
specified subgroups. There were no significant 
interactions among subgroups stratified by sex, age, 
BMI, CVD history, diabetes mellitus status, baseline 
kidney function, serum albumin, and low-density lipo-
protein cholesterol level, suggesting that the significant 
association of hs-CRP with adverse outcome existed 
across the subgroups (Figure 2).
Predictive Ability of hs-CRP for the 
Primary Outcome
The predictive ability of hs-CRP for the primary out-
come was tested by comparing area under the re-
ceiver-operating characteristics curves, c-statistics, 
net reclassification improvement, and integrated 
discrimination improvement (Table 3 and Figure S3) 
among the base, base+hs-CRP, renal, and renal+hs-
CRP models. The area under the receiver-oper-
ating characteristics curve and c-statistic for the 
base model were 0.764 (0.722–0.806) and 0.776 
(0.737–0.816), respectively. Adding eGFR and pro-
teinuria to the base model increased area under the 
receiver-operating characteristics curve (P=0.02), c-
statistic (P=0.01), category-free net reclassification 
Figure 1. Cumulative incidence curve for (A) the primary and individual secondary outcomes of (B) eMACE, (C) all-cause 
mortality, and (D) composite renal outcome according to hs-CRP group.
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improvement (P=0.02), and integrated discrimination 
improvement (P=0.04). However, adding hs-CRP to 
the base or renal model did not improve any of the 
4 prediction indexes (Table 3 and Figure S3). These 
findings suggest that the predictive ability of hs-CRP 
was not greater than that of conventional factors.
DISCUSSION
In this study, we showed that hs-CRP level was low 
in Korean patients with CKD, and this low-grade in-
flammation was associated with significantly higher 
risk of adverse cardiovascular outcome and mortality. 
However, hs-CRP was not associated with CKD pro-
gression, and the predictive performance of hs-CRP 
for the primary outcome was not greater than that of 
conventional factors.
Inflammation plays an important role in ath-
erosclerotic plaque progression, vulnerability, 
and thrombogenicity28–30 and has become an es-
tablished nontraditional risk factor for CVEs.31,32 
Patients with CKD have generally been considered 
to have high inflammation levels, and many studies 
have shown that serum concentrations of inflam-
matory markers are elevated in these patients.33 
However, in our KNOW-CKD cohort subjects, the 
median hs-CRP level was only 0.6 mg/L, and 61.1% 
had hs-CRP level <1.0  mg/L. This inflammation 
level is still lower than the median hs-CRP level of 
2.5  mg/L in another CKD cohort of the Western 
population given the similar kidney function in 
the 2 CKD cohorts.34 Our literature review on this 
issue also indicated that Korean patients and other 
East Asian cohorts had lower hs-CRP levels than 
Western populations although we could not directly 
compare hs-CRP levels among groups (Table S3). 
Interestingly, our cohort involving patients with CKD 
alone had lower hs-CRP level than the Western 
population at high risk of major cardiovascular 
event but with preserved kidney function. These 
findings led us to question whether such low-grade 
inflammation could perform well as a biomarker for 
Korean patients with CKD.
Despite low inflammation levels in East Asians, 
hs-CRP well predicted adverse cardiovascular 
outcomes. In a health screening program cohort 
composed of 268  803 Korean middle-aged peo-
ple, there was a significant association of hs-CRP 
level with risk of CVEs and all-cause mortality.14 
Similar findings were also observed in Japanese 
and Chinese cohort studies.35,36 Interestingly, our 
Table 2. HRs for the Primary Composite Outcome and Secondary Outcomes According to hs-CRP Groups
hs-CRP Category
Model 1 Model 2 Model 3 Model 4
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Primary composite outcome*
<1.0 mg/L 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
1.0–2.99 mg/L 1.28 (0.90–1.81) 0.16 1.31 (0.87–1.99) 0.20 1.33 (0.87–2.03) 0.19 1.76 (1.06–2.95) 0.03
≥3.0 mg/L 2.10 (1.46–3.03) <0.01 2.24 (1.43–3.51) <0.01 2.08 (1.30–3.33) <0.01 2.72 (1.55–4.77) <0.01
eMACE
<1.0 mg/L 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
1.0–2.99 mg/L 1.24 (0.82–1.88) 0.30 1.35 (0.83–2.22) 0.23 1.44 (0.87–2.38) 0.15 2.16 (1.09–4.31) 0.03
≥3.0 mg/L 1.71 (1.07–2.73) 0.02 1.84 (1.04–3.28) 0.04 1.86 (1.04–3.42) 0.04 2.51 (1.09–5.79) 0.03
All-cause mortality
<1.0 mg/L 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
1.0–2.99 mg/L 1.11 (0.64–1.94) 0.71 1.08 (0.54–2.19) 0.82 1.05 (0.51–2.15) 0.90 1.65 (0.82–3.33) 0.16
≥3.0 mg/L 2.82 (1.68–4.72) <0.01 2.94 (1.51–5.71) <0.01 2.57 (1.26–5.22) 0.01 2.78 (1.33–5.80) 0.01
Composite renal outcome†
<1.0 mg/L 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
1.0–2.99 mg/L 1.03 (0.85–1.26) 0.75 1.08 (0.87–1.35) 0.26 1.03 (0.64–1.67) 0.90 0.98 (0.76–1.27) 0.91
≥3.0 mg/L 1.00 (0.77–1.29) 0.97 0.79 (0.58–1.09) 0.15 0.68 (0.32–1.45) 0.32 0.83 (0.59–1.18) 0.30
Model 1: without adjustment. Model 2: adjusted for age, sex, alcohol intake, smoking status, Charlson comorbidity index, socioeconomic status, educational 
status, body mass index, systolic blood pressure, use of renin-angiotensin system blockers, β-blockers, diuretics, and use of statin. Model 3: adjusted for model 
2 plus laboratory parameters such as estimated glomerular filtration rate, urine protein-to-creatinine ratio, high-density lipoprotein cholesterol, serum phosphate, 
and serum albumin. Model 4: time-varying model adjusted for age, sex, alcohol intake, smoking status, Charlson comorbidity index, socioeconomic status, 
educational status, use of renin-angiotensin system blockers, β-blockers, diuretics, use of statin, baseline estimated glomerular filtration rate, urine protein-to-
creatinine ratio, and time-varying covariates at any given visit such as body mass index, systolic blood pressure, high-density lipoprotein cholesterol, serum 
phosphate, and serum albumin. eMACE indicates extended major cardiovascular events; HR, hazard ratio; and hs-CRP, high-sensitivity C-reactive protein.
*Primary composite outcome included eMACE, cardiac death, or all-cause death, whichever came first.
†Composite kidney outcome included a ≥50% decline in estimated glomerular filtration rate or the onset of end-stage kidney disease, whichever came first.Dow
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KNOW-CKD cohort had a low inflammation level, 
and an elevated hs-CRP level was significantly as-
sociated with a higher risk of eMACE and mortality. 
It is uncertain whether such low-grade inflammation 
can increase cardiovascular risk in these patients. 
However, it should be noted that the association 
of hs-CRP with primary outcome, eMACE, and all-
cause death was statistically significant, particularly 
when hs-CRP was ≥3.0 mg/L; patients with hs-CRP 
level in this range belong to the high-risk category 
as suggested by the American Heart Association 
and Centers for Disease Control and Prevention in 
2003.25 Therefore, it can be presumed that the effect 
of hs-CRP begins to show when it increases beyond 
a certain threshold. Given that hs-CRP level varies 
among different ethnic groups and is relatively low 
in East Asians, further studies should address this 
issue on the appropriate cut-off point of hs-CRP to 
identify patients at high risk of CVD, particularly in 
East Asians.
This low hs-CRP level might result in lower inci-
dence of CVEs and mortality in our cohort. We noted 
that the incidence rates of the primary outcome, 
nonfatal CVEs, and all-cause death in our cohort 
were 2.32, 1.57, and 0.98 per 100 person-years, 
respectively. Similar findings were also reported by 
a Japanese CKD cohort study.37 Compared with 
such fewer CVE rates in East Asian cohorts, stud-
ies from the US cohorts showed higher incidence 
rates of all CVE (3.3–3.8 per 100 person-years).4,38 A 
schematic figure on different incidence rates of major 
cardiovascular event among studies is presented in 
Figure S4. Because inflammation greatly contributes 
to atherosclerosis and CVE, we surmised that lower 
CVE rates in our cohort might be partly explained by 
low inflammation level. Thus, similar hs-CRP levels 
among different ethnic groups should be interpreted 
with caution in the context of other cardiovascular 
risk factors.
Chronic inflammation has also been suggested to 
be a significant determinant of CKD progression.34,39 
However, there is controversy on the association of 
hs-CRP level with kidney function decline.40–42 In our 
study, hs-CRP was not associated with adverse kidney 
outcome. In line with our findings, Sarnak et al40 ana-
lyzed the data from the Modification of Diet in Renal 
Disease Study and found no significant association of 
hs-CRP level with CKD progression. In addition, in a 
population-based cohort of 4926 people, a higher hs-
CRP level failed to predict the development of CKD.42 
Figure 2. Forest plot for subgroup analysis.
BMI indicates body mass index; CVD, cardiovascular disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; and 
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Taken together, these findings suggest that many 
other factors beyond inflammation are involved in CKD 
progression.
Several shortcomings of this study should be 
considered. First, given the observational nature 
of the study, it is possible that potential confound-
ing factors were not entirely controlled. However, 
this study included only patients with CKD and an-
alyzed the data using various models after rigor-
ous adjustment of measured covariates. Second, 
we measured only hs-CRP to assess inflammatory 
status. There are other inflammatory markers such 
as tumor necrosis factor α and IL-6. Several stud-
ies showed that these markers were more strongly 
associated with CVEs, mortality, and kidney failure 
than with hs-CRP.33,38,41,42 As aforementioned, hs-
CRP level was significantly lower in East Asians; to 
our knowledge, no studies have collectively exam-
ined many inflammatory markers.35,43 Thus, future 
studies are warranted to find alternative surrogates 
of inflammation in Korean patients with CKD. Third, 
hs-CRP level was measured at the local laboratory of 
each participating center and not at the central lab-
oratory. This may raise concerns about imprecision 
and bias for measuring hs-CRP. However, all labo-
ratories in our study used the same direct enzymatic 
assay and measured hs-CRP level within 24 hours of 
sampling. Furthermore, we thoroughly adjusted for 
participating centers and other time-varying covari-
ates that could potentially affect outcomes. Fourth, 
based on our findings, the clinical utility of hs-CRP 
may be limited because the predictive ability of hs-
CRP for adverse cardiovascular outcomes was not 
superior to that of conventional risk factors. This can 
be attributed to relatively fewer CVEs and deaths in 
our cohort, which may not provide statistical power. 
In addition, adding hs-CRP to the renal model did 
not improve predictive performance. Notably, the hs-
CRP level was higher as eGFR was lower, suggesting 
higher inflamed status in advanced CKD. Thus, the 
renal model might reflect this inflammatory condition. 
This can also explain the failure of hs-CRP for im-
proving predictive performance. Finally, because the 
hs-CRP level varies according to ethnic group and 
because we included only Korean patients, our find-
ings may not be generalizable to other populations.
In conclusion, we showed that hs-CRP level was 
low in Korean patients with CKD. Elevated hs-CRP 
level was associated with a higher risk of CVD and 
mortality. However, hs-CRP did not predict adverse 
kidney outcomes, and the predictive performance of 
hs-CRP was not superior to that of conventional fac-
tors. Our findings add to the existing evidence that 
inflammation can help to predict adverse outcomes 
but also raise questions on the clinical utility of hs-
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Data collection and survey instruments 
Demographic details of age, sex, smoking status, alcohol consumption, medical history, and 
comorbid diseases were obtained from the KNOW-CKD database. Smoking status was 
classified as never, former, or current. Anthropometric data, including height and weight, 
were collected at enrollment. BMI was calculated as initial body weight divided by height 
squared (kg/m2). Blood pressure was measured using an electronic sphygmomanometer in the 
sitting position after subjects had been in a relaxed state for at least 5 minutes. After 
overnight fasting, blood samples were collected and sent to the central laboratory of KNOW-
CKD (Lab Genomics, Seongnam, Korea) for measurements of creatinine. Other biochemical 
analyses were performed at the local laboratory of each participating center. The following 
laboratory parameters were measured at baseline and annually thereafter: complete blood cell 
count, fasting glucose, blood urea nitrogen, creatinine, albumin, calcium, and phosphorus. 
Lipid profiles for total cholesterol, triglycerides, HDL-C, and LDL-C, iron profiles (including 
total iron-binding capacity and serum ferritin), and hs-CRP were measured at baseline, year 
1, and year 3. Serum hs-CRP level was measured at each center using commercially available 
enzyme-linked immunosorbent assay kits. 
 We measured creatinine level using a calibration traceable to isotope dilution mass 
spectrometry method and calculated the eGFR using the CKD Epidemiologic Collaboration 
equation.44 Along with blood samples, urine samples were also immediately sent to the 
central laboratory for proteinuria measurement. The urine protein-to-creatinine ratio was 
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Statistical analysis  
Continuous variables with normal distribution were expressed as mean with SD, and those 
with skewed distribution were described as median with interquartile range. The Shapiro–
Wilk normality test was used for normality testing. Categorical variables are presented as 
number and percentage. One-way analysis of variance was used for normal distributed data, 
and the Kruskal–Wallis test was used for skewed data to identify differences and compare 
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Table S1. Adverse outcome event rates among groups classified by the hs-CRP groups. 
 Total hs-CRP groups 
<1.0 mg/L 1.0 to 2.99 mg/L ≥ 3.0 mg/L 
No. of participants 2018 1233 508 277 
Person-year 7934.9 4882.4 2029.3 1023.1 
Primary composite outcome*     
  Events, (%) 184 (9.1%) 94 (7.6%) 49 (9.7%) 41 (14.8%) 
  Events per 100 person-yr 2.32 1.93 2.41 4.01 
Secondary outcome     
eMACE     
  Events, (%) 125 (6.2%) 67 (5.4%) 34 (6.7%) 24 (8.7%) 
  Events per 100 person-yr 1.57 1.37 1.68 2.33 
All-cause mortality     
  Events, (%) 80 (4.0%) 39 (3.2%) 18 (3.5%) 23 (8.3%) 
  Events per 100 person-yr 0.98 0.78 0.86 2.16 
Composite kidney outcome†     
  Events, (%) 544 (27.0%) 330 (26.8%) 145 (28.5%) 69 (24.9%) 
  Events per 100 person-yr 7.63 7.56 7.85 7.50 
*Primary composite outcome included eMACE, cardiac death or all-cause death, whichever came first. 
†Composite kidney outcome included a ≥50% decline in eGFR or the onset of ESKD, whichever came first. 
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Table S2. Hazard ratios for the primary composite outcome according to hs-CRP tertile and quintile groups.  
 Model 1 Model 2 Model 3 Model 4 
hs-CRP category HR  [95% CI ] P HR  [95% CI ] P HR  [95% CI ] P HR  [95% CI ] P 
Tertile group         
<0.38 mg/L 1.00 [Reference]  1.00 [Reference]  1.00 [Reference]  1.00 [Reference]  
0.38 to 1.20 mg/L 1.17 [0.79-1.73]  0.43 1.15 [0.72-1.85]  0.56 1.23 [0.76-2.00]  0.40 1.01 [0.52-2.00]  0.76 
≥1.21 mg/L 1.90 [1.33-2.72] <0.01 1.94 [1.24-3.03] <0.01 1.92 [1.20-3.06] <0.01 2.24 [1.24-4.06] <0.01 
Quintile group         
<0.20 mg/L 1.00 [Reference]  1.00 [Reference]  1.00 [Reference]  1.00 [Reference]  
0.20 to 0.43 mg/L 1.63 [1.01-2.61]  0.04 1.77 [0.95-3.31]  0.07 1.87 [0.99-3.53]  0.06 1.16 [0.56-2.37]  0.69 
0.44 to 0.90 mg/L  1.49 [0.92-2.43]  0.11 1.32 [0.72-2.42]  0.37 1.38 [0.74-2.56]  0.31 1.03 [0.37-2.85]  0.95 
0.91 to 2.10 mg/L 1.71 [1.03-2.84]  0.04 1.83 [1.03-3.25]  0.04 1.83 [1.02-3.30]  0.04 1.60 [0.75-3.42]  0.22 
≥2.11 mg/L 2.44 [1.56-3.82] <0.01 2.37 [1.35-4.18] <0.01 2.33 [1.30-4.20] <0.01 2.66 [1.08-6.55] <0.01 
Note: Model 1: without adjustment   
Model 2: adjusted for age, sex, alcohol intake, smoking status, Charlson comorbidity index, socioeconomic status, educational status, BMI, SBP, 
use of renin-angiotensin system blockers, beta blockers, diuretics, and use of statin 
Model 3: adjusted for Model 2 plus laboratory parameters such as eGFR, urine protein-to-creatinine ratio, HDL-C, serum phosphate, and serum 
albumin 
Model 4: Time-varying model adjusted for age, sex, alcohol intake, smoking status, Charlson comorbidity index, socioeconomic status, 
educational status, use of renin-angiotensin system blockers, beta blockers, diuretics, use of statin, baseline eGFR, urine protein-to-creatinine 
ratio, and time-varying covariates at any given visit such as BMI, SBP, HDL-C, serum phosphate, and serum albumin 
BMI, body mass index; CI, confidence interval; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein-cholesterol; HR, 
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Table S3. hs-CRP levels among different ethnic groups. 
Studies Population Ethnicity Group Number eGFR (mL/min/1.73 m2) hs-CRP (mg/L)  
MESA 21 General Caucasians Men 1253 N/A 1.3 (0.2-2.4) 
 
  Women 1349 N/A 2.5 (0.4-4.5) 
  Chinese Men 388 N/A 0.8 (0.3-1.4) 
   Women 413 N/A 1.0 (0.3-1.4) 
  African Americans Men 836 N/A 1.8 (0.4-3.2) 
   Women 1035 N/A 3.4 (0.4-6.5) 
  Hispanics Men 716 N/A 1.9 (0.5-3.4) 
 
  Women 681 N/A 3.0 (0.5-5.5) 
MESA 45 General Multi-ethnic All 6437 77.7±16.2 N/A 
JUPITER 46 General Multi-ethnic Rosuvasatatin 8901 73.3 (64.6-83.7) 4.2 (2.8-7.1) 
 
  Placebo 8901 73.6 (64.6-84.1) 4.3 (2.8-7.1) 
CRIC 47 CKD Multi-ethnic All 2399 44.1±13.9 2.5 (1.0-6.0) 
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  Non-Hispanic black All 1650 43.5±16.3 3.3 (1.3-8.2) 
  Hispanic All 497 39.0±15.2 2.5 (1.0-5.7) 
ADVANCE 49 DM Multi-ethnic All 3865 71.48±16.86 1.8 (0.9-4.1) 
CANTOS 50 MI Multi-ethnic Placebo 1597 79.0 (65.0-93.0) 4.1 (2.8-6.9) 
 
  Canakinumab 1619 78.5 (64.0-93.0) 4.2 (2.8-7.1) 
JNIC 43 General Japanese Men 5213 N/A 0.6 (0.3-1.3) 
  
Japanese Women 7071 N/A 0.5 (0.2-0.9) 
DDCRT 6 51 DM Japanese All 3573 N/A 0.8 (0.1-1.7) 
CKD-JAC 37,52 CKD Japanese All 2966 28.9 ±12.2 1.0 (0.4-2.0) 
Liu et al. 35 General Chinese All 90517 N/A 0.7 (0.3-1.9) 
Sung et al. 14 General Korean Men 151962 N/A 0.6 (0.3-1.3) 
 
  Women 116841 N/A 0.4 (0.1-1.1) 
CALLISTO 53 DM/CVD Korean All 1561 N/A 0.3 (0.01-7.5) 
KNOW-CKD CKD Korean All 2018 46.6 (28.7-73.8) 0.6 (0.2-1.7) 
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ADVANCE, Action in Diabetes and Vascular Disease; CALLISTO, Correlation of plasma hsCRP concentrations and cardiovascular risk in Korean 
population: Preterax and Diamicron Modified Release Controlled Evaluation; CANTOS, Canakinumab Anti-Inflammatory Thrombosis Outcomes 
Study; CKD-JAC, Chronic Kidney Disease Japan Cohort; CRIC, Chronic Renal Insufficiency Cohort;DDCRT, Diabetes Distress and Care 
Registry at Tenri; eGFR, estimated glomerular filtration rate; JUPITER, The Justification for the Use of statins in Primary prevention: an 
Intervention Trial Evaluating Rosuvastatin; JNIC, The Japan NCVC-Collaborative Inflammation Cohort; KNOW-CKD, KoreaN Cohort Study for 
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Base model: age, sex, alcohol intake, smoking status, Charlson comorbidity index, socioeconomic status, educational status, baseline BMI, SBP, 
HDL-C, total cholesterol, and serum albumin  
Base + hs-CRP model: base model + hs-CRP 
Renal model: base model + estimated glomerular filtration rate, urine protein-to-creatinine ratio  
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Figure S4. Different incidence rates of MACE among studies. 
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CANTOS 50: nonfatal myocardial infarction, any nonfatal stroke, or cardiovascular death 
CRIC 48: composite atherosclerotic events (myocardial infarction, stroke, or peripheral arterial disease) or death outcome 
MESA 45: coronary heart disease events (myocardial infarction, CHD deaths, definite angina, and probable angina if followed by coronary 
revascularization), stroke, stroke death, and other atherosclerotic deaths coronary heart disease events 
CKD-JAC 37: cardiovascular events (fatal and nonfatal myocardial infarction, angina pectoris, sudden death, congestive heart failure, 
arrhythmias, cerebrovascular disorder, chronic arteriosclerosis obliterans, and aortic dissection) and all-cause death 
KNOW-CKD: composite of eMACE (unstable angina, myocardial infarction, or coronary intervention/surgery, hospitalization for heart failure, 
or ischemic or hemorrhagic stroke or symptomatic arrhythmia), cardiac deaths, or all-cause deaths  
CANTOS, Canakinumab Anti-Inflammatory Thrombosis Outcomes Study; CHD, coronary heart disease; CKD-JAC, Chronic Kidney Disease 
Japan Cohort; CRIC, Chronic Renal Insufficiency Cohort; eMACE, non-fatal CVEs, or cardiac deaths; KNOW-CKD, KoreaN Cohort Study for 
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